| 0 (0%) | 01-19 18:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 112.71 | 1-year : | 131.65 |
| Resists | First : | 96.5 | Second : | 112.71 |
| Pivot price | 93.61  |
|||
| Supports | First : | 92.03 | Second : | 89.27 |
| MAs | MA(5) : | 94.57  |
MA(20) : | 93.12 |
| MA(100) : | 86.1 |
MA(250) : | 77.78 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 77 |
D(3) : | 76.8 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 96.5 | Low : | 61.24 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AZN ] has closed below upper band by 36.4%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 94.75 - 95.2 | 95.2 - 95.62 |
| Low: | 92.34 - 92.87 | 92.87 - 93.36 |
| Close: | 93.54 - 94.35 | 94.35 - 95.12 |
Mon, 19 Jan 2026
AstraZeneca (AZN): EMA Considers Enhertu for Breast Cancer Treat - GuruFocus
Mon, 19 Jan 2026
Azerbaijan Allocates Over AZN 5.3 Billion to Oil and Gas in 2025 - Caspian Post
Mon, 19 Jan 2026
AstraZeneca's Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial - Finviz
Mon, 19 Jan 2026
EMA takes up ENHERTU combo that tops standard HER2 breast cancer care - Stock Titan
Sat, 17 Jan 2026
Is AstraZeneca (LSE:AZN) Still Sensibly Priced After A 31.3% One Year Share Gain - simplywall.st
Fri, 16 Jan 2026
AstraZeneca (AZN) Weighs FDA Fast-Track Risks Amid Legal Concerns - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 3,100 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 16.7 (%) |
| Shares Short | 8,320 (K) |
| Shares Short P.Month | 9,970 (K) |
| EPS | 3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.59 |
| Profit Margin | 16.1 % |
| Operating Margin | 24.1 % |
| Return on Assets (ttm) | 9 % |
| Return on Equity (ttm) | 21.6 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 15.61 |
| Sales Per Share | 18.75 |
| EBITDA (p.s.) | 6.58 |
| Qtrly Earnings Growth | 78 % |
| Operating Cash Flow | 15,140 (M) |
| Levered Free Cash Flow | 9,980 (M) |
| PE Ratio | 31.35 |
| PEG Ratio | 0 |
| Price to Book value | 3.18 |
| Price to Sales | 5.03 |
| Price to Cash Flow | 19.32 |
| Dividend | 0.5 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|